Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Radiotherapy for newly diagnosed oligometastatic prostate cancer.

Boeri L, Sharma V, Karnes RJ.

Lancet. 2018 Dec 1;392(10162):2327-2328. doi: 10.1016/S0140-6736(18)32598-4. Epub 2018 Oct 21. No abstract available.

2.

Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.

Larbi A, Dallaudière B, Pasoglou V, Padhani A, Michoux N, Vande Berg BC, Tombal B, Lecouvet FE.

Prostate. 2016 Aug;76(11):1024-33. doi: 10.1002/pros.23196. Epub 2016 May 16.

PMID:
27197649
3.

The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.

Kim J, Park JS, Ham WS.

Investig Clin Urol. 2017 Sep;58(5):307-316. doi: 10.4111/icu.2017.58.5.307. Epub 2017 Aug 8. Review.

4.

Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations.

Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM.

Nat Rev Urol. 2017 Jan;14(1):15-25. doi: 10.1038/nrurol.2016.175. Epub 2016 Oct 11. Review.

5.

OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.

Supiot S, Rio E, Pacteau V, Mauboussin MH, Campion L, Pein F.

BMC Cancer. 2015 Sep 25;15:646. doi: 10.1186/s12885-015-1579-0.

6.

Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer.

Niazi T, Elakshar S, Stroian G.

Curr Opin Support Palliat Care. 2018 Sep;12(3):351-358. doi: 10.1097/SPC.0000000000000371.

PMID:
29979320
7.

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT.

BMC Cancer. 2017 Jun 29;17(1):453. doi: 10.1186/s12885-017-3455-6.

8.

[Radiotherapy for local disease in metastatic prostate cancer.]

Cambeiro M, Calvo FA.

Arch Esp Urol. 2018 Mar;71(3):298-305. Review. Spanish.

PMID:
29633951
9.

The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients.

Guler OC, Engels B, Onal C, Everaert H, Van den Begin R, Gevaert T, de Ridder M.

Clin Transl Oncol. 2018 Apr;20(4):484-490. doi: 10.1007/s12094-017-1736-9. Epub 2017 Aug 9.

PMID:
28795303
10.

Stereotactic radiotherapy in oligometastatic cancer.

Kennedy TAC, Corkum MT, Louie AV.

Chin Clin Oncol. 2017 Sep;6(Suppl 2):S16. doi: 10.21037/cco.2017.06.20. Review.

11.

[(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results.

Pasqualetti F, Panichi M, Sainato A, Matteucci F, Galli L, Cocuzza P, Ferrazza P, Coraggio G, Pasqualetti G, Derosa L, Sollini M, Mannelli L, Ortori S, Monzani F, Ricci S, Greco C, Fabrini MG, Erba PA.

Radiat Oncol. 2016 Jan 22;11:9. doi: 10.1186/s13014-016-0586-x.

12.

[Oligometastatic prostate cancer. concept and implications.]

Carrasco Valiente J, Ruiz García JM, Requena Tapia MJ.

Arch Esp Urol. 2018 Mar;71(3):239-246. Review. Spanish.

PMID:
29633944
13.

Oligometastatic prostate cancer: Reality or figment of imagination.

Foster CC, Weichselbaum RR, Pitroda SP.

Cancer. 2018 Dec 6. doi: 10.1002/cncr.31860. [Epub ahead of print] Review.

PMID:
30521067
14.

Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.

Joice GA, Rowe SP, Pienta KJ, Gorin MA.

Curr Opin Urol. 2017 Nov;27(6):533-541. doi: 10.1097/MOU.0000000000000449. Review.

PMID:
28863016
15.

The Role of Local Therapy for Oligometastatic Prostate Cancer: Should We Expect a Cure?

Nair R, Lamb BW, Geurts N, Alghazo O, Lam W, Lawrentschuk N, Murphy DG.

Urol Clin North Am. 2017 Nov;44(4):623-633. doi: 10.1016/j.ucl.2017.07.013. Review.

PMID:
29107278
16.

Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer.

De Bleser E, Tran PT, Ost P.

Curr Opin Urol. 2017 Nov;27(6):587-595. doi: 10.1097/MOU.0000000000000441. Review.

PMID:
28816714
17.

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation.

Shenderov E, Gorin MA, Kim S, Johnson PT, Allaf ME, Partin AW, Pomper MG, Antonarakis ES, Pienta KJ, Rowe SP.

Urol Case Rep. 2017 Dec 19;17:22-25. doi: 10.1016/j.eucr.2017.12.011. eCollection 2018 Mar.

18.

[Surgical treatment of local disease in metastatic prostate cancer.]

Gaya JM, Huguet J, Breda A, Palou J.

Arch Esp Urol. 2018 Mar;71(3):288-297. Review. Spanish.

PMID:
29633950
19.

[Radiotherapy of oligometastatic pelvic node relapses in patients with prostate cancer].

Supiot S, Doré M, Rio E.

Cancer Radiother. 2017 Oct;21(6-7):495-497. doi: 10.1016/j.canrad.2017.07.017. Epub 2017 Aug 25. French.

PMID:
28847462
20.

Oligometastatic prostate cancer: Metastases-directed therapy?

Van Poppel H, De Meerleer G, Joniau S.

Arab J Urol. 2016 Jul 20;14(3):179-82. doi: 10.1016/j.aju.2016.06.004. eCollection 2016 Sep. Review.

Supplemental Content

Support Center